The PROTAGORAS 2.0 Study to Identify Sizing and Planning Predictors for Optimal Outcomes in Abdominal Chimney Endovascular Procedures.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 26 06 2020
revised: 18 10 2020
accepted: 10 11 2020
pubmed: 13 2 2021
medline: 25 5 2021
entrez: 12 2 2021
Statut: ppublish

Résumé

The aim was to identify predictors of adequate pre-operative sizing and planning for chimney endovascular aortic repair (ChEVAR) in order to reduce the incidence of persistent type Ia endoleaks (IaELs) without influencing chimney graft (CG) patency. Consecutive patients who underwent ChEVAR between January 2009 and December 2017 at a single centre were evaluated retrospectively. Included were patients treated with one device combination (Medtronic Endurant mated with Getinge Advanta V12/iCast) and placement of single or double CG. The freedom from IaEL related re-interventions and primary CG patency was estimated by measuring aortic stent graft oversizing (OS), total neck length (TNL), and a composite parameter (L-OS: TNL [mm] + OS [%]). Seventy-three patients who underwent placement of 101 CGs (45 single, 28 double) met the inclusion criteria. The median radiological follow up was 25.5 (interquartile range [IQR] 12-48) months. Freedom from IaEL related re-intervention was achieved in 94.6% with a median OS of 38.5% (IQR 30%-44%, p = .004), TNL 19 mm (16-25 mm, p = .62), and L-OS 59 (51-65, p = .018). Primary CG patency was achieved in 95% of the cases with a median OS of 36% (29%-42%, p = .008), TNL 19 mm (15.5-26 mm, p = .91), and L-OS 57 (50-64, p = .005). By using the receiver operating characteristic curve, an optimal cut off to prevent IaEL related re-interventions was identified by an OS of 30% (p < .001; L-OS 55, p = .006) and to avoid CG stenosis/occlusions by OS 42% (p < .001; L-OS 65, p < .001). In multivariable analysis, aortic endograft OS was the only independent parameter preventive for IaEL related re-intervention (odds ratio, 0.78; 95% confidence interval, 0.61-0.99). With the Endurant-Advanta V12/iCast combination, an aortic stent graft OS of at least 30% (range 30%-42%) should be used to avoid type Ia endoleaks and likewise to ensure CG patency.

Identifiants

pubmed: 33573913
pii: S1078-5884(20)31040-6
doi: 10.1016/j.ejvs.2020.11.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

591-602

Informations de copyright

Copyright © 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

Stefano Fazzini (S)

Department of Vascular Surgery, St Franziskus Hospital, Münster, Germany; Unit of Vascular Surgery, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy. Electronic address: dr.stefano.fazzini@gmail.com.

Ombretta Martinelli (O)

Unit of Vascular Surgery, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Giovanni Torsello (G)

Institute for Vascular Research, St. Franziskus Hospital, Münster, Germany.

Martin Austermann (M)

Department of Vascular Surgery, St Franziskus Hospital, Münster, Germany.

Marco D Pipitone (MD)

Department of Vascular Surgery, St Franziskus Hospital, Münster, Germany.

Giovanni F Torsello (GF)

Department of Radiology, Charité Campus Virchow-Klinikum, Charité University Medicine, Berlin, Germany.

Luigi Irace (L)

Unit of Vascular Surgery, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Konstantinos P Donas (KP)

Department of Vascular Surgery and Research Vascular Centre, Asclepios Clinic Langen, University of Frankfurt, Langen, Hessen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH